BPC-157 and TB-500: adverse events in the published literature

BPC-157: safety trials exist, long-term data does not

BPC-157 entered clinical development for inflammatory bowel disease under the code PL14736 and was reported safe in that clinical trial setting. Development reviews are nonetheless clear that there is no approved formulation, no validated dosing regimen and no completed Phase II trial, and that the compound has not been approved by the FDA or comparable regulators because comprehensive clinical studies confirming benefit in humans are absent.

A safety signal from a trial in one indication does not generalise to other uses, other routes or longer exposure. None of those has been studied.

The replication problem is a safety problem too

More than eighty per cent of published studies on BPC-157 (a member of the repair peptides class) are attributable by author affiliation to a single research group at the University of Zagreb. This is usually discussed as a limitation on efficacy claims, but it applies equally to safety: an adverse effect that one laboratory’s models do not surface is not the same as an adverse effect that does not exist.

Independent replication across separate laboratories is the normal precondition for treating any preclinical finding — favourable or unfavourable — as robust.

Thymosin beta-4: human safety data from a different route

Thymosin beta-4 has been through registered human trials, including a Phase II study in dry eye (NCT01387347), a double-blind placebo-controlled dose-response study in venous stasis ulcers (NCT00832091), and a Phase III programme with RGN-259 in neurotrophic keratopathy. Its safety has additionally been assessed across a series of nonclinical toxicology and safety pharmacology studies.

Those trials studied topical and ophthalmic administration. Systemic injection for musculoskeletal repair — the use most readers are researching — has not been characterised in humans, so the trial safety record does not describe it.

The fragment question applies here as well: TB-500 as sold is commonly a fragment rather than full-length thymosin beta-4, and safety data on the full-length protein does not automatically transfer.

What is not known

For BPC-157: no long-term human safety data, no efficacy trial completed, and a preclinical base that has not been independently replicated at scale. For TB-500: no human safety data for systemic injection, and uncertainty about whether the marketed material matches the studied molecule (see the BPC-157 & TB-500 overview for what is sold).

Neither compound is an authorised medicine, so neither is covered by a pharmacovigilance system collecting adverse-event reports from real-world use. Where this page says an adverse effect has not been reported, that reflects the absence of a reporting system as much as the absence of an effect; the recovery goal page summarises the same evidence.